SCD and metabolic dysfunction-associated steatotic liver disease: As SCD1 and DGAT2 enzymes are potential targets for the treatment of NAFLD and clinical trials are ongoing, PHF2 and KDM7A could provide potential therapeutic targets in treating NAFLD.